The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist.
CQA 206-291, a new D2 dopamine receptor agonist with a biphasic dopaminergic profile, was given to six patients with idiopathic Parkinson's disease after overnight drug withdrawal. With incremental single oral doses of CQA, a dose-related, clinically significant, and prolonged antiparkinsonian effect was observed. Most subjects experienced drowsiness after the drug while a minority of subjects experienced nausea and/or vomiting or postural hypotension. Further study of this drug in humans is indicated.
Temlett
J A
JA
University Department of Clinical Neurology, National Hospital for Nervous Diseases, London, England.
Quinn
N P
NP
Marsden
C D
CD
Lataste
X
X
Jaton
A L
AL
D000368:Aged; D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000502:physiology
D015259:Dopamine Agents; D004873:Ergolines; D011954:Receptors, Dopamine; C059483:CQA 206-291